OptiBiotix Health has issued 800,000 shares priced at £0.08 ($0.11) a share in a private placement to raise £0.064m ($0.089m).
OptiBiotix is a UK-based life sciences company.
Go deeper with GlobalData
US-based biopharmaceutical company CTI BioPharma has issued an underwritten public offering of shares of its common stock. The company will grant underwriters a 30-day option to buy additional shares.
The proceeds are intended to be used towards the completion of the PAC203 clinical trial and for general corporate purposes, including research and development, and pre-clinical and clinical trials.
CTI BioPharma has appointed Leerink Partners as the sole book-running manager and JMP Securities as the senior lead manager for the transaction.
Needham & Company and Oppenheimer & Co have been appointed as lead managers, and O’Melveny & Myers as the legal advisor.
US-based biopharmaceutical company NovaBay Pharmaceuticals has issued 1.7 million shares priced at $3.52 a share in a private placement to raise $5.98m.
OP Financial Investments has subscribed to the placement.
NovaBay Pharmaceuticals has appointed China Kington Asset Management as the placement agent for the transaction.
